Core Insights - The pharmaceutical manufacturing industry in China is projected to see an increase in export value, with a reported export value of 17.74 billion yuan in October 2025, reflecting a year-on-year growth of 2.9% [1] - Cumulatively, from January to October 2025, the total export value reached 195.22 billion yuan, marking a year-on-year increase of 12.1% [1] Company Insights - Listed companies in the pharmaceutical sector include: Guoyao Modern (600420), Kunming Pharmaceutical Group (600422), Pian Zai Huang (600436), Qianjin Pharmaceutical (600479), Tianyao Pharmaceutical (600488), Guoyao Shares (600511), Lianhuan Pharmaceutical (600513), Hefei China (603122), Kanghui Pharmaceutical (603139), Shapuaisi (603168), Aoxiang Pharmaceutical (603229), and Daclin (603233) [1] Industry Report - The report titled "Market Development Trends and Strategic Assessment of China's Pharmaceutical Manufacturing Industry from 2025 to 2031" was published by Zhiyan Consulting, indicating a focus on the future growth and strategic direction of the industry [1][2] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, providing comprehensive industry research reports and tailored consulting services [2]
2025年1-10月全国医药制造业出口货值为1952.2亿元，累计增长12.1%
Chan Ye Xin Xi Wang·2025-12-05 03:00